Activity of RBx 11760, a novel biaryl oxazolidinone, against Clostridium difficile

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 5, 2011, Pages 1087-1095

  Mathur, Tarun ^a   Kumar, Manoj ^a,b   Barman, Tarani K ^a,b   Kumar, G Ram ^a,b   Kalia, Vandana ^a,b   Singhal, Smita ^a,b   Samuel Raj, V ^a,b   Upadhyay, Dilip J ^a,b   Das, Biswajit ^a,b   Bhatnagar, Pradip K ^a,b  

^a RANBAXY RESEARCH LABORATORIES   (India)

^b DAIICHI SANKYO CO   (Japan)

Author keywords

CDI; Hamster infection; Sporulation; Toxin

Indexed keywords

LINEZOLID; METRONIDAZOLE; OXAZOLIDINONE DERIVATIVE; RBX 11760; UNCLASSIFIED DRUG; VANCOMYCIN;

ANAEROBIC BACTERIUM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; DRUG EFFICACY; HISTOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PROTEIN SYNTHESIS; SPOROGENESIS; SURVIVAL TIME;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL TOXINS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; CRICETINAE; DISEASE MODELS, ANIMAL; HUMANS; MESOCRICETUS; METRONIDAZOLE; OXAZOLIDINONES; SPORES, BACTERIAL; VANCOMYCIN;

EID: 79954626175     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr033     Document Type: Article

References (37)

1. Sunenshine RH, McDonald LC. Clostridium difficile-associated disease: new challenges from an established pathogen. CCJM 2006; 73: 187-97.
2. Torpy JM, Lynm C, Glass RM. Clostridium difficile colitis. JAMA 2009; 301: 988.
3. Vonberg RP, Reichardt C, Behnke M et al. Costs of nosocomial Clostridium difficile-associated diarrhoea. J Hosp Infect 2008; 70: 15-20.
4. Bartlett JG, Perl TM. The new Clostridium difficile-what does it mean? New Engl J Med 2005; 353: 2503-5.
5. McDonald LC, Owings M, Jernigan DB. Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003. Emerg Infect Dis 2006; 12: 409-15.
6. Kelly CP, LaMont JT. Clostridium difficile-more difficult than ever. New Engl J Med 2008; 359: 1932-40.
7. Borgmann S, Kist M, Jakobiak T et al. Increased number of Clostridium difficile infections and prevalence of Clostridium difficile PCR ribotype 001 in southern Germany. Eurosurveillance 2008; 13: 1-5.
8. McDonald LC. Clostridium difficile: responding to a new threat from an old enemy. Infect Control Hosp Epidemiol 2005; 26: 672-5.
9. Freeman J, Baines SD, Saxton K et al. Effect of metronidazole on growth and toxin production by epidemic Clostridium difficile PCR ribotypes 001 and 027 in a human gut model. J Antimicrob Chemother 2007; 60: 83-91.
10. Mylonakis E, Ryan ET, Calderwood SB. Clostridium difficile-associated diarrhea. Arch Intern Med 2001; 161: 525-33.
11. Starr J. Clostridium difficile associated diarrhoea: diagnosis and treatment. BMJ 2005; 331: 498-501.
12. Zar FA, Bakkanagari SR, Moorthi KM et al. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007; 45: 302-7.
13. Baines SD, O'Connor R, Freeman J et al. Emergence of reduced susceptibility to metronidazole in Clostridium difficile. J Antimicrob Chemother 2008; 62: 1046-52.
14. Pepin J, Alary ME, Valiquette L et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis 2005; 40: 1591-7.
15. Barker RH Jr, Dagher R, Davidson DM et al. Tolevamer a novel toxin-binding polymer: overview of preclinical pharmacology and physicochemical properties. Aliment Pharm Ther 2006; 24: 1525-34.
16. Taylor NS, Bartlett J. Binding of Clostridium difficile cytotoxin and vancomycin by anion-exchange resins. J Infect Dis 1980; 141: 92-7.
17. Dendukuri N, Costa V, McGregor M et al. Probiotic therapy for the prevention and treatment of Clostridium difficile-associated diarrhea: a systematic review. CMAJ 2005; 173: 167-70.
18. McFarland LV, Elmer GW, Surawicz CM. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol 2002; 97: 1769-75.
19. Peláez T, Alcala L, Alonso R et al. In vitro activity of ramoplanin against Clostridium difficile, including strains with reduced susceptibility to vancomycin or with resistance to metronidazole. Antimicrob Agents Chemother 2005; 49: 1157-9.
20. Sullivan KM, Spooner LM. Fidaxomicin: a macrocyclic antibiotic for the management of Clostridium difficile infection. Ann Pharmacother 2010; 44: 352-9.
21. Citron DM, Warren YA, Tyrrell KL et al. Comparative in vitro activity of REP3123 against Clostridium difficile and other anaerobic intestinal bacteria. J Antimicrobial Chemother 2009; 63: 972-6.
22. Lowy I, Molrine DC, Leav BA. Treatment with monoclonal antibodies against Clostridium difficile toxins. New Engl J Med 2010; 362: 197-205.
23. Kyne L. Clostridium difficile-beyond antibiotics. New Engl J Med 2010; 362: 264-5.
24. Betriu C, Redondo M, Boloix A et al. Comparative activity of linezolid and other new agents against methicillin-resistant Staphylococcus aureus and teicoplanin-intermediate cogulase-negative staphylococci. J Antimicrobial Chemother 2001; 48: 911-3.
25. Ackermann G, Adler D, Rodloff AC. In vitro activity of linezolid against Clostridium difficile. J Antimicrobial Chemother 2003; 51: 743-5.
26. Peláez T, Alonso R, Pérez C et al. In vitro activity of linezolid against Clostridium difficile. Antimicrobial Agents Chemother 2002; 46: 1617-8.
27. Barman TK, Pandya M, Mathur T et al. Novel biaryl oxazolidinones: in vitro and in vivo activities with pharmacokinetics in an animal model. Int J Antimicrob Agents 2009; 33: 280-4.
28. Clinical and Laboratory Standards Institute. Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria-Sixth Edition: Approved Standard M11-A6. CLSI, Villanova, PA, USA, 2004.
29. Yagi BH, Zurenko GE. An in vitro time-kill assessment of linezolid and anaerobic bacteria. Anaerobe 2003; 9: 1-3.
30. Ochsner UA, Bell SJ, O'Leary AL et al. Inhibitory effect of REP3123 on toxin and spore formation in Clostridium difficile, and in vivo efficacy in a hamster gastrointestinal infection model. J Antimicrobial Chemother 2009; 63: 964-71.
31. Hamouda T, Shih AY, Baker JR Jr. A rapid staining technique for the detection of the initiation of germination of bacterial spores. Lett Appl Microbiol 2002; 34: 86-90.
32. Gerber M, Walch C, Loffler B et al. Effect of sub-MIC concentrations of metronidazole, vancomycin, clindamycin and linezolid on toxin gene transcription and production in Clostridium difficile. J Med Microbiol 2008; 57: 776-83.
33. McVay CS, Rolfe RD. In vitro and in vivo activities of nitazoxanide against Clostridium difficile. Antimicrob Agents Chemother 2000; 44: 2254-8.
34. Kalia V, Miglani R, Purnapatre KP et al. Mode of action of ranbezolid against staphylococci and structural modeling studies of its interaction with ribosomes. Antimicrob Agents Chemother 2009; 53: 1427-33.
35. Lode H, von der Höh N, Ziege S et al. Ecological effects of linezolid versus amoxicillin/clavulanic acid on the normal intestinal microflora. Scand J Infect Dis 2001; 33: 899-903.
36. Sambol SP, Tang JK, Merrigan MM et al. Infection of hamsters with epidemiologically important strains of Clostridium difficile. J Infect Dis 2001; 183: 1760-6.
37. Lyras D, O'Connor JR, Howarth PM et al. Toxin B is essential for virulence of Clostridium difficile. Nature 2009; 458: 1176-9.